Interleukin 15: A key cytokine for immunotherapy

Patidar, Manoj; Yadav, Naveen; Dalai, Sarat K.

doi:10.1016/j.cytogfr.2016.06.001

Cited by 123 publications

(118 citation statements)

References 113 publications

Supporting

Mentioning

116

Contrasting

Order By: Relevance

“…Depending on the drug, administration can be achieved through repetitive single i.v. doses, continuous infusion, or subcutaneous dosing (5,6,8). One of these clinical studies, in which rhIL-15 (0.3-3 μg/kg by i.v.…”

Section: Discussionmentioning

confidence: 99%

“…One could also foresee inflammatory settings, in which IL-15-mediated exhaustion of NK cells can be beneficial by capping their response. However, in the therapeutic setting where IL-15 is being used to enhance patient immune responses to tumor, inducing NK cell exhaustion is clearly detrimental (4,5,40). There are currently a number of clinical trials (ref.…”

Section: Discussionmentioning

confidence: 99%

“…Among the strategies being evaluated preclinically to address this issue, utilization of cytokines to induce NK cell persistence and expansion seems to dominate current clinical trials. While a number of cytokines have been tested, IL-15 appears to be the most logical choice due to its known physiologic role on NK cell development and homeostasis without stimulating regulatory T cells (4)(5)(6)(7). Several clinical trials (NCT02395822, NCT01385423, NCT03388632, NCT01727076, NCT01572493, NCT01021059, NCT01369888, NCT01875601, NCT01885897, NCT02191098, NCT01946789, NCT02989844, NCT03054909, NCT02384954) are underway using IL-15 with dosing strategies, including i.v.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect

Felices¹,

Lenvik²,

McElmurry³

et al. 2018

JCI Insight

195

150

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect

Felices¹,

Lenvik²,

McElmurry³

et al. 2018

JCI Insight

195

150

View full text Add to dashboard Cite

“…In addition to its effects on T and NK cells, it also modulates B cells, monocytes, macrophages, DC, mast cells, and neutrophils (Patidar, Yadav et al 2016). IL-15 is a member of the common gamma chain (γc) cytokine family, as its heterotrimeric receptor shares one of its three subunits, γc, with a number of other cytokines, IL-2, IL-4, IL-7, IL-9 and IL-21.…”

Section: Pathobiologymentioning

confidence: 99%

Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Associations, Outcomes, and Pathobiology—Thirty Years of Progress but Still Much to Be Done

Stern

Divito

2017

Journal of Investigative Dermatology

View full text Add to dashboard Cite

“…Deletion of IL-15, its receptor, or its downstream signaling proteins results in NK cell lymphopenia [125]. The IL-15α chain can also be secreted and endocytosed, and subsequently trans-present IL-15 to other cells [126,127]. …”

Section: Enhancing Nk Cell Efficacy With Cytokinesmentioning

confidence: 99%

Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy

Koch

Tesar

2017

Transfus Med Hemother

View full text Add to dashboard Cite

Immunotherapy has the potential to support and expand the body's own armamentarium of immune effector functions, which have been circumvented during malignant transformation and establishment of cancer and is presently considered to be the most promising treatment option for cancer patients. Recombinant antibody technologies have led to a multitude of novel antibody formats, which are in clinical development and hold great promise for future therapies. Among these formats, bispecific antibodies are extremely versatile due to their high efficacy to recruit and activate anti-tumoral immune effector cells, their excellent safety profile, and the opportunity for use in combination with cellular therapies. This review article summarizes the latest developments in cancer immunotherapy using immuno-engagers for recruiting T cells and NK cells to the tumor site. In addition to antibody formats, malignant cell targets, and immune cell targets, opportunities for combination therapies, including check point inhibitors, cytokines and adoptive transfer of immune cells, will be summarized and discussed.

show abstract

Interleukin 15: A key cytokine for immunotherapy

Cited by 123 publications

References 113 publications

Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect

Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect

Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Associations, Outcomes, and Pathobiology—Thirty Years of Progress but Still Much to Be Done

Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy

Contact Info

Product

Resources

About